Your browser doesn't support javascript.
loading
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei, Heng; Li, Chenggong; Jiang, Huiwen; Zhao, Xinying; Huang, Zhiping; Jin, Dan; Guo, Tao; Kou, Haiming; Liu, Lin; Tang, Lu; Yin, Ping; Wang, Zhihui; Ai, Lisha; Ke, Sha; Xia, Yimeng; Deng, Jun; Chen, Lei; Cai, Li; Sun, Chunyan; Xia, Linghui; Hua, Gaoquan; Hu, Yu.
Afiliação
  • Mei H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. hmei@hust.edu.cn.
  • Li C; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China. hmei@hust.edu.cn.
  • Jiang H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Zhao X; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Huang Z; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Jin D; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Guo T; Institute of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, 434020, China.
  • Kou H; Institute of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, 434020, China.
  • Liu L; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Tang L; Zhejiang Cellyan Biotechnology Co. Ltd, Jiaxin, 314001, China.
  • Yin P; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Wang Z; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Ai L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Ke S; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Xia Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Deng J; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Chen L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Cai L; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
  • Sun C; Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Xia L; Drug Clinical Trial Institution, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Hua G; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Hu Y; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
J Hematol Oncol ; 14(1): 161, 2021 10 09.
Article em En | MEDLINE | ID: mdl-34627333
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / ADP-Ribosil Ciclase 1 / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Hematol Oncol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / ADP-Ribosil Ciclase 1 / Antígeno de Maturação de Linfócitos B / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Hematol Oncol Ano de publicação: 2021 Tipo de documento: Article